Free Trial

Leerink Partners' Rating of Rocket Pharmaceuticals on 5/28/2025

On May 28, 2025, Leerink Partners updated its outlook on Rocket Pharmaceuticals (NASDAQ:RCKT) with the action "Reiterated Rating", keeping a "Market Perform" rating. MarketBeat All Access subscribers can view the full ratings details, 12-month ROI, historical price target changes, and related news coverage on this page.

unlock icon  Upgrade to MarketBeat All Access

This premium research tool is available to MarketBeat All Access subscribers only. Log in to your account or sign up below.

Already have an account? Log in here.